



State of Louisiana
Department of Health and Hospitals
Bureau of Health Services Financing

MEMORANDUM

DATE: October 14, 2019

TO: Louisiana Medicaid Fee-for-Service Pharmacy Program and Managed Care Organizations

FROM: Melwyn Wendt
Pharmacy Director

SUBJECT: Point of sale edits – Tosymra (Sumatriptan nasal spray)

Effective December 1, 2019, the Louisiana Medicaid Fee for Service (FFS) Pharmacy Program and Managed Care Organizations (MCO) will update **clinical edits at Point of Sale** (POS) for Tosymra (Sumatriptan nasal spray). The updates apply to FFS and Medicaid MCOs (Aetna, AmeriHealth Caritas, Healthy Blue, Louisiana Healthcare Connections and United Healthcare). This measure was approved at the May 2019 meeting of the Louisiana Drug Utilization Review board.

Tosymra (Sumatriptan nasal spray) Point of Sale edits are as follows.

- **Diagnosis code requirement.**

- Diagnosis requirement for age < 18 years:

G43.0*, G43.1*, G43.7*	Migraine
------------------------	----------

*Any number or letter combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code.

- **Quantity limit.**

- Six (6) 10 mg single-dose disposable units/30 days.

An incoming pharmacy claim for Tosymra will deny if the quantity is above the limit and/or if a diagnosis code is missing or invalid.